A Phase One, Open Label, Two-period, Two-treatment, Fixed Sequence, Cross-over Study To Estimate The Effect Of Multiple Dose Rifampin On The Single Dose Pharmacokinetics Of Pf-06463922 In Healthy Volunteers
Latest Information Update: 27 Dec 2019
At a glance
- Drugs Lorlatinib (Primary) ; Rifampicin
- Indications Cancer; Lymphoma; Neuroblastoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 20 Dec 2019 Results of effect of rifampin on the pharmacokinetics and safety of lorlatinib has published in the Advances in Therapy.
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 10 Aug 2016 Status changed from recruiting to active, no longer recruiting.